两剂量赛尼哌在预防移植肾急性排斥反应中的临床效果  

Two Doses Regimen of Zenapax in the Prevention of Acute Renal Allograft Rejection

作　　者：王中华[1] 王毅[1] 杨伟峰[1] 秦国庆[1] 李建军[1] 

机构地区：[1]南华大学附属第二医院肾移植中心,湖南衡阳421001

出　　处：《美国中华临床医学杂志》2006年第1期28-30,共3页American Journal of Chinese Clinical Medicine

摘　　要：目的探讨赛尼哌在预防同种肾异体移植术后急性排斥反应（AR）的作用，并评估其安全性。方法44例肾移植患者随机分为赛尼哌治疗组22例与对照组22例，冶疗组在术前及术后14d分别静滴赛尼哌一个剂量，对照组以生理盐水为安慰剂，观察期为6个月。结果赛尼哌组在3个月内急性排斥反应发生率显著低于对照组（P〈0．05），在感染及副作用方面与对照组无显著性差异，随访期内，人肾均存活。结论赛尼哌是一种强效安全的免疫抑制剂，可显著降低移植肾AR的发生率。Objective To investigate the use of zenapax in the prevention of acute rejection （AR） in renal transplant recipients. Methotis 44 patients were randomly divided into two groups, i.e. treatment group （ n = 22） and control group （ n = 22）. One doses zenapax was given within 24 h before pretransplantation and 14 days after transplantation separately. Observation period lasted for 6 months. Results Acute rejection rate was lower in the zenapax group as compared to tire control group within 6 months, No differences occurred between zenapax group and control group in infection and adverse events, Both patient and graft were survival in follow up time. Conclusion Zenapax is a safe and effective induction therapy in sensitized recipients, and could prevent AR in renal transplantation recipients.

关 键 词：肾移植 赛尼哌 急性排斥反应 预防 剂量 

分 类 号：R699.2[医药卫生—泌尿科学]